Kadmon Holdings, Inc. Securities Litigation

If you purchased a significant amount of shares of Kadmon Holdings, Inc. (NYSE: KDMN), you have certain options. Investors should contact us.

 

Lawsuit Overview

Defendant:Kadmon Holdings, Inc.
Date Filed:April 2nd, 2021
Sector:Health Care
Industry:Major Pharmaceuticals
Class Start Date:October 1st, 2020
Class End Date:March 10th, 2021

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Belumosudil NDA was incomplete and/or deficient; (ii) the additional new data that the Company submitted in support of the Belumosudil NDA in response to an information request from the FDA materially altered the NDA submission; (iii) accordingly, the initial Belumosudil NDA submission lacked the degree of support that the Company had led investors to believe; (iv) accordingly, the FDA was likely to extend the PDUFA target action date to review the Belumosudil NDA; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Kadmon Holdings, Inc.

 
First Identified Complaint

Rafik Tadros, et al. v. Kadmon Holdings, Inc., et al.

Date Filed:April 2nd, 2021
Class Period Start:October 1st, 2020
Class Period End:March 10th, 2021
First Identified Complaint Filings
#Document TitleFiling Date